Literature DB >> 15625342

Rofecoxib, Merck, and the FDA.

Peter S Kim, Alise S Reicin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15625342     DOI: 10.1056/NEJM200412303512719

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.

Authors:  W W Bolten
Journal:  Ann Rheum Dis       Date:  2005-06-07       Impact factor: 19.103

2.  Unbalanced reporting of benefits and harms in abstracts on rofecoxib.

Authors:  Anders W Jørgensen; Karsten Juhl Jørgensen; Peter C Gøtzsche
Journal:  Eur J Clin Pharmacol       Date:  2010-02-17       Impact factor: 2.953

3.  Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies.

Authors:  Włodzimierz Matysiak; Barbara Jodłowska-Jedrych
Journal:  Protoplasma       Date:  2010-08-19       Impact factor: 3.356

4.  Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process.

Authors:  Margaret T Whitstock; Christopher M Pearce; Stephen C Ridout; Elizabeth J Eckermann
Journal:  BMC Public Health       Date:  2011-05-21       Impact factor: 3.295

Review 5.  Overstating the evidence: double counting in meta-analysis and related problems.

Authors:  Stephen J Senn
Journal:  BMC Med Res Methodol       Date:  2009-02-13       Impact factor: 4.615

6.  The route of science: Labyrinths and algorithms - Inspirations by human papillomavirus testing and cervical cancer.

Authors:  Mehmet Uhri; Binnur Önal
Journal:  Cytojournal       Date:  2015-10-23       Impact factor: 2.091

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.